Physician profile
Robert E Thaler
NPI 1073995635
$6,572.31
in general payments reported to CMS, 2019-2025
47 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $190 · 2021: $193 · 2022: $897 · 2023: $1,483 · 2024: $1,546 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,549.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $957.95 | 2022-2025 | Ubrelvy, Qulipta, Synthroid |
| Astrazeneca Pharmaceuticals Lp | $789.86 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $627.66 | 2019-2025 | |
| Lilly USA, LLC | $593.14 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $447.44 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Gilead Sciences, INC. | $263.90 | 2019-2025 | |
| Amgen INC. | $254.38 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $253.98 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.70 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $188.58 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $188.27 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.79 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $146.63 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Phathom Pharmaceuticals, INC. | $134.68 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $131.41 | 2019-2023 | Xarelto |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Thaler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.